The AIDS Healthcare Foundation (AHF) today called on Gilead Sciences and Merck to immediately register and distribute the three-in-one, once daily lifesaving HIV treatment, Atripla, in developing countries.

When Atripla first received approval from the Food and Drug Administration (FDA) in July of 2006, advocates like AHF applauded the production of a single, once-a-day drug as a landmark step in treating HIV. However, since its approval, little progress has been made in expanding the availability of the treatment in the developing world, where only 28% of those in need of treatment were able to access it as of December 2006.

"This treatment is a standard therapy in the United States.

Breasts move far more than ordinary bras are designed to cope with and they also bounce more during exercise – up to 21 cm rather than the maximum 16 cm bounce measured in past studies, according to new research.

Ordinary bras can stop the bouncing but the new study by University of Portsmouth scientist Dr Joanna Scurr shows that breasts also move side-to-side and in and out and estimates are that more than 50 percent of women experience breast pain when exercising, regardless of cup size.

Dr Scurr’s study also found that breasts move as much during slow jogging as they do at maximum sprint speed.

An important finding has been made by McMaster researchers about Fragile X Syndrome (FXS), a sex-linked genetic disorder that affects approximately one in 4,000 males and one in 6,000 females.

FXS is the most common genetic disorder associated with mental impairment. The affected gene (FMR1) leads to inactivation of the FMR1 gene product, known as the fragile X mental retardation protein (FMRP).

Brain development in the absence of this protein leads to cognitive effects, learning and memory problems, attention deficit, hyperactivity and autistic behaviors. Many children go undiagnosed with Fragile X.

Melbourne, Florida -- Symetrics Industries, LLC announced today an award from the U.S. Army for approximately 300 Improved Data Modems (IDM) for installation on Army aircraft. The contract value will be between US$7 and US$8 million, once final negotiations are completed. The IDM-304 is the Army version of the Improved Data Modems that Symetrics has been delivering to the U.S. Air Force for over 14 years.

Symetrics President and CEO, Mitch Garner stated, "We are absolutely thrilled with this order because it demonstrates the Army's confidence in our ability to execute a long-term, high volume production effort. The IDM-304 is the cornerstone of the Army's airborne element of the Tactical Internet, and Symetrics is proud to be able to provide this critical equipment."

Nearly 30 years after Nobel laureate Linus Pauling famously and controversially suggested that vitamin C supplements can prevent cancer, a team of Johns Hopkins scientists have shown that in mice at least, vitamin C - and potentially other antioxidants - can indeed inhibit the growth of some tumors ¯ just not in the manner suggested by years of investigation.

The conventional wisdom of how antioxidants such as vitamin C help prevent cancer growth is that they grab up volatile oxygen free radical molecules and prevent the damage they are known to do to our delicate DNA.

Scientists at Johns Hopkins have developed a mouse model for schizophrenia in which a mutated gene linked to schizophrenia can be turned on or off at will.

The researchers developed the transgenic mouse by inserting the gene for mutant Disrupted-In-Schizophrenia-1 (DISC-1) into a normal mouse, along with a promoter that enables the gene to be switched on or off. Mutant DISC-1 was previously identified in a Scottish family with a strong history of schizophrenia and related mental disorders.

The study was performed in the laboratory of Mikhail Pletnikov, M.D., Ph.D., in the Department of Psychiatry and Behavioral Sciences.